Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks
by on Tuesday, July 10th, 2012 | No Comments
Condition: Melanoma
Intervention: Biological: Coxsackievirus A21
Sponsors: Viralytics; Viralytics
Recruiting – verified July 2012
Continued here: Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks